Ironwood Pharmaceuticals, Inc. (IRWD) Stock Analysis
A live, multi-source view of Ironwood Pharmaceuticals, Inc. (IRWD): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United States · 100 employees · ironwoodpharma.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Ironwood Pharmaceuticals, Inc. (IRWD) had a market capitalization of $703.9M, a trailing P/E of 5.4 (forward 2.8) and a beta of 0.21; the shares traded in a 52-week range of $1.05 – $5.78 (277.0% over the year).
- Market cap
- $703.9M
- Enterprise value
- $1.02B
- Trailing P/E
- 5.4
- Forward P/E
- 2.8
- EPS (trailing)
- $0.79
- EPS (forward)
- $1.50
- Payout ratio
- 0.0%
- 52-week range
- $1.05 – $5.78
- 52-week change
- 277.0%
- Beta
- 0.21
- Average volume
- 2.2M
- Shares outstanding
- 165.2M
- Short % of float
- 11.94%
- Profit margin
- 33.4%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Ironwood Pharmaceuticals, Inc. (IRWD) last closed at $4.26 (the last completed close before that scan).
Technicals at the scan: RSI 51 (neutral territory), price 0.0% versus its 20-day average, 20-day versus 50-day average spread +1.9%, MACD histogram -0.01.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 69/100.
Next scheduled company event: in 62 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for IRWD in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
IRWD has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Ironwood Pharmaceuticals, Inc. (IRWD) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell IRWD.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.